Trial Profile
A Randomized, Double- Blind, Placebo- Controlled, Multi- Center Phase 3 Study to Determine the Treatment Effect of Denosumab in Subjects with Non- Metastatic Breast Cancer Receiving Aromatase Inhibitor Therapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Feb 2024
Price :
$35
*
At a glance
- Drugs Denosumab (Primary) ; Aromatase inhibitors; Zoledronic acid
- Indications Postmenopausal osteoporosis
- Focus Registrational; Therapeutic Use
- Acronyms ABCSG18
- Sponsors Amgen
- 05 Aug 2022 Status changed from active, no longer recruiting to completed.
- 26 Jul 2022 Planned End Date changed from 26 Jul 2022 to 31 Aug 2022.
- 07 Jun 2022 Results of final long term outcomes analysis presented at the 58th Annual Meeting of the American Society of Clinical Oncology